Search Results

You are looking at 71 - 80 of 110 items for :

  • "aromatase inhibitor" x
  • All content x
Clear All
Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

TEXT and SOFT trials, more high-risk young women are being treated with ovarian suppression and aromatase inhibitor therapy, which may help improve long-term outcomes for this population moving forward. 23 – 25 In the present study, only approximately

Full access

Melinda L. Telli, William J. Gradishar, and John H. Ward

Endocrine Therapy Still Unclear For postmenopausal HR-positive breast cancer, the most common option, among many, is upfront aromatase inhibitor therapy for 5 years. High-level evidence exists to extend therapy for 5 additional years in select patients, but

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

tamoxifen or an aromatase inhibitor. However, such a change overlooks the significant difference in biological behavior associated with DCIS compared with ADH. ADH incurs a far lower risk of breast cancer, approximately one-half that of low-grade DCIS

Full access

Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov

. 10.1016/S1470-2045(09)70314-6 20005174 2. Dowsett M , Cuzick J , Ingle J , . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J Clin Oncol 2010 ; 28 : 509 – 518 . 19949017 10.1200/JCO

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

influence of ethnicity and race on the efficacy and safety of raloxifene as a risk reduction agent. Table 4 Rates of Breast Cancer in the NSABP Study of Tamoxifen and Raloxifene (STAR) Trial – 81 Months Median Follow-Up Aromatase Inhibitors

Full access

, improved multidisciplinary communication between medical teams and patients, and using 5-FU in the case of cap delay enhanced the delivery of concurrent chemoXRT. AB2018-13. Management of Bone Health in Patients With Breast Cancer on Aromatase Inhibitors

Full access

Leslie R. Schover, Ying Yuan, Bryan M. Fellman, Evan Odensky, Pamela E. Lewis, and Paul Martinetti

aromatase inhibitors, 7 direct genital damage from pelvic radiation therapy, 8 - 10 and genital graft-versus-host disease. 11 Urinary and fecal incontinence often lead to avoidance of sexual contact. 12 The recent NCCN Clinical Practice Guidelines in

Full access

Kathleen Harnden and Kimberly Blackwell

/ABCSG XX) . Presented at the 2013 San Antonio Breast Cancer Symposium ; December 13, 2013 ; San Antonio, Texas . 25. Llombart A Frassoldati A Paija O . Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal

Full access

Parijatham S. Thomas

(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo

Full access

Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson

oophorectomy or aromatase inhibitor use with established breast cancer. However, with additional postintervention follow-up, a seemingly paradoxical situation arose. Despite the decreasing HR trend seen during the early postintervention period, the summary